APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Chagas Disease Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Chagas Disease Drug Industry Research Report 2026

Report ID 173976730522 December 2025120 pages

Choose your research edition.

Industry ResearchChagas Disease Drug Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Chagas Disease Drug Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Chagas Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chagas Disease Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Chagas Disease Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Chagas Disease Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Chagas Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Chagas Disease Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Chagas Disease Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Chagas Disease Drug include Eisai Co Ltd, Sanofi, Novartis AG, GlaxoSmithKline Plc, Bayer AG, AstraZeneca Plc, Oblita Therapeutics BVBA, Merck & Co Inc and Kancera AB, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Chagas Disease Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Chagas Disease Drug Market by Company

Eisai Co Ltd

Sanofi

Novartis AG

GlaxoSmithKline Plc

Bayer AG

AstraZeneca Plc

Oblita Therapeutics BVBA

Merck & Co Inc

Kancera AB

Humanigen Inc

Grupo Praxis Pharmaceutical SA

Daiichi Sankyo Co Ltd

Chagas Disease Drug Segment by Type

Cz-007

Cz-008

D-121

DNDI-0690

EPLBS-1246

EPLBS-967

Others

Chagas Disease Drug Segment by Application

Hospital

Clinic

Others

Chagas Disease Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chagas Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chagas Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chagas Disease Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Chagas Disease Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Chagas Disease Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Chagas Disease Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Chagas Disease Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Chagas Disease Drug Sales (k units) of Manufacturers (2021-2026) Table 7. Global Chagas Disease Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Chagas Disease Drug Revenue of Manufacturers (2021-2026) Table 9. Global Chagas Disease Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Chagas Disease Drug Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Chagas Disease Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Chagas Disease Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Chagas Disease Drug, Product Type & Application Table 14. Global Chagas Disease Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Chagas Disease Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Eisai Co Ltd Company Information Table 19. Eisai Co Ltd Business Overview Table 20. Eisai Co Ltd Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Eisai Co Ltd Chagas Disease Drug Product Portfolio Table 22. Eisai Co Ltd Recent Developments Table 23. Sanofi Company Information Table 24. Sanofi Business Overview Table 25. Sanofi Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Sanofi Chagas Disease Drug Product Portfolio Table 27. Sanofi Recent Developments Table 28. Novartis AG Company Information Table 29. Novartis AG Business Overview Table 30. Novartis AG Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Novartis AG Chagas Disease Drug Product Portfolio Table 32. Novartis AG Recent Developments Table 33. GlaxoSmithKline Plc Company Information Table 34. GlaxoSmithKline Plc Business Overview Table 35. GlaxoSmithKline Plc Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. GlaxoSmithKline Plc Chagas Disease Drug Product Portfolio Table 37. GlaxoSmithKline Plc Recent Developments Table 38. Bayer AG Company Information Table 39. Bayer AG Business Overview Table 40. Bayer AG Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Bayer AG Chagas Disease Drug Product Portfolio Table 42. Bayer AG Recent Developments Table 43. AstraZeneca Plc Company Information Table 44. AstraZeneca Plc Business Overview Table 45. AstraZeneca Plc Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. AstraZeneca Plc Chagas Disease Drug Product Portfolio Table 47. AstraZeneca Plc Recent Developments Table 48. Oblita Therapeutics BVBA Company Information Table 49. Oblita Therapeutics BVBA Business Overview Table 50. Oblita Therapeutics BVBA Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Oblita Therapeutics BVBA Chagas Disease Drug Product Portfolio Table 52. Oblita Therapeutics BVBA Recent Developments Table 53. Merck & Co Inc Company Information Table 54. Merck & Co Inc Business Overview Table 55. Merck & Co Inc Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Merck & Co Inc Chagas Disease Drug Product Portfolio Table 57. Merck & Co Inc Recent Developments Table 58. Kancera AB Company Information Table 59. Kancera AB Business Overview Table 60. Kancera AB Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Kancera AB Chagas Disease Drug Product Portfolio Table 62. Kancera AB Recent Developments Table 63. Humanigen Inc Company Information Table 64. Humanigen Inc Business Overview Table 65. Humanigen Inc Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Humanigen Inc Chagas Disease Drug Product Portfolio Table 67. Humanigen Inc Recent Developments Table 68. Grupo Praxis Pharmaceutical SA Company Information Table 69. Grupo Praxis Pharmaceutical SA Business Overview Table 70. Grupo Praxis Pharmaceutical SA Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Grupo Praxis Pharmaceutical SA Chagas Disease Drug Product Portfolio Table 72. Grupo Praxis Pharmaceutical SA Recent Developments Table 73. Daiichi Sankyo Co Ltd Company Information Table 74. Daiichi Sankyo Co Ltd Business Overview Table 75. Daiichi Sankyo Co Ltd Chagas Disease Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Daiichi Sankyo Co Ltd Chagas Disease Drug Product Portfolio Table 77. Daiichi Sankyo Co Ltd Recent Developments Table 78. Global Chagas Disease Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 79. Global Chagas Disease Drug Sales by Region (2021-2026) & (k units) Table 80. Global Chagas Disease Drug Sales Market Share by Region (2021-2026) Table 81. Global Chagas Disease Drug Sales by Region (2027-2032) & (k units) Table 82. Global Chagas Disease Drug Sales Market Share by Region (2027-2032) Table 83. Global Chagas Disease Drug Revenue by Region (2021-2026) & (US$ Million) Table 84. Global Chagas Disease Drug Revenue Market Share by Region (2021-2026) Table 85. Global Chagas Disease Drug Revenue by Region (2027-2032) & (US$ Million) Table 86. Global Chagas Disease Drug Revenue Market Share by Region (2027-2032) Table 87. North America Chagas Disease Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. North America Chagas Disease Drug Sales by Country (2021-2026) & (k units) Table 89. North America Chagas Disease Drug Sales by Country (2027-2032) & (k units) Table 90. North America Chagas Disease Drug Revenue by Country (2021-2026) & (US$ Million) Table 91. North America Chagas Disease Drug Revenue by Country (2027-2032) & (US$ Million) Table 92. Europe Chagas Disease Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. Europe Chagas Disease Drug Sales by Country (2021-2026) & (k units) Table 94. Europe Chagas Disease Drug Sales by Country (2027-2032) & (k units) Table 95. Europe Chagas Disease Drug Revenue by Country (2021-2026) & (US$ Million) Table 96. Europe Chagas Disease Drug Revenue by Country (2027-2032) & (US$ Million) Table 97. Asia Pacific Chagas Disease Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Asia Pacific Chagas Disease Drug Sales by Country (2021-2026) & (k units) Table 99. Asia Pacific Chagas Disease Drug Sales by Country (2027-2032) & (k units) Table 100. Asia Pacific Chagas Disease Drug Revenue by Country (2021-2026) & (US$ Million) Table 101. Asia Pacific Chagas Disease Drug Revenue by Country (2027-2032) & (US$ Million) Table 102. South America Chagas Disease Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. South America Chagas Disease Drug Sales by Country (2021-2026) & (k units) Table 104. South America Chagas Disease Drug Sales by Country (2027-2032) & (k units) Table 105. South America Chagas Disease Drug Revenue by Country (2021-2026) & (US$ Million) Table 106. South America Chagas Disease Drug Revenue by Country (2027-2032) & (US$ Million) Table 107. Middle East and Africa Chagas Disease Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Middle East and Africa Chagas Disease Drug Sales by Country (2021-2026) & (k units) Table 109. Middle East and Africa Chagas Disease Drug Sales by Country (2027-2032) & (k units) Table 110. Middle East and Africa Chagas Disease Drug Revenue by Country (2021-2026) & (US$ Million) Table 111. Middle East and Africa Chagas Disease Drug Revenue by Country (2027-2032) & (US$ Million) Table 112. Global Chagas Disease Drug Sales by Type (2021-2026) & (k units) Table 113. Global Chagas Disease Drug Sales by Type (2027-2032) & (k units) Table 114. Global Chagas Disease Drug Sales Market Share by Type (2021-2026) Table 115. Global Chagas Disease Drug Sales Market Share by Type (2027-2032) Table 116. Global Chagas Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 117. Global Chagas Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 118. Global Chagas Disease Drug Revenue Market Share by Type (2021-2026) Table 119. Global Chagas Disease Drug Revenue Market Share by Type (2027-2032) Table 120. Global Chagas Disease Drug Price by Type (2021-2026) & (US$/unit) Table 121. Global Chagas Disease Drug Price by Type (2027-2032) & (US$/unit) Table 122. Global Chagas Disease Drug Sales by Application (2021-2026) & (k units) Table 123. Global Chagas Disease Drug Sales by Application (2027-2032) & (k units) Table 124. Global Chagas Disease Drug Sales Market Share by Application (2021-2026) Table 125. Global Chagas Disease Drug Sales Market Share by Application (2027-2032) Table 126. Global Chagas Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 127. Global Chagas Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 128. Global Chagas Disease Drug Revenue Market Share by Application (2021-2026) Table 129. Global Chagas Disease Drug Revenue Market Share by Application (2027-2032) Table 130. Global Chagas Disease Drug Price by Application (2021-2026) & (US$/unit) Table 131. Global Chagas Disease Drug Price by Application (2027-2032) & (US$/unit) Table 132. Key Raw Materials Table 133. Raw Materials Key Suppliers Table 134. Chagas Disease Drug Distributors List Table 135. Chagas Disease Drug Customers List Table 136. Chagas Disease Drug Industry Trends Table 137. Chagas Disease Drug Industry Drivers Table 138. Chagas Disease Drug Industry Restraints Table 139. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Chagas Disease Drug Product Image Figure 5. Global Chagas Disease Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Chagas Disease Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Chagas Disease Drug Sales (2021-2032) & (k units) Figure 8. Global Chagas Disease Drug Average Price (US$/unit) & (2021-2032) Figure 9. Cz-007 Product Image Figure 10. Cz-008 Product Image Figure 11. D-121 Product Image Figure 12. DNDI-0690 Product Image Figure 13. EPLBS-1246 Product Image Figure 14. EPLBS-967 Product Image Figure 15. Others Product Image Figure 16. Hospital Product Image Figure 17. Clinic Product Image Figure 18. Others Product Image Figure 19. Global Chagas Disease Drug Revenue Share by Manufacturers in 2025 Figure 20. Global Manufacturers of Chagas Disease Drug, Manufacturing Sites & Headquarters Figure 21. Global Top 5 and 10 Chagas Disease Drug Players Market Share by Revenue in 2025 Figure 22. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global Chagas Disease Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 24. Global Chagas Disease Drug Sales by Region in 2025 Figure 25. Global Chagas Disease Drug Revenue by Region in 2025 Figure 26. North America Chagas Disease Drug Market Size by Country in 2025 Figure 27. North America Chagas Disease Drug Sales Market Share by Country (2021-2032) Figure 28. North America Chagas Disease Drug Revenue Market Share by Country (2021-2032) Figure 29. United States Chagas Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Canada Chagas Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Mexico Chagas Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Europe Chagas Disease Drug Market Size by Country in 2025 Figure 33. Europe Chagas Disease Drug Sales Market Share by Country (2021-2032) Figure 34. Europe Chagas Disease Drug Revenue Market Share by Country (2021-2032) Figure 35. Germany Chagas Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. France Chagas Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. U.K. Chagas Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Italy Chagas Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Russia Chagas Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Spain Chagas Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Netherlands Chagas Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Switzerland Chagas Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Sweden Chagas Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Poland Chagas Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Asia Pacific Chagas Disease Drug Market Size by Country in 2025 Figure 46. Asia Pacific Chagas Disease Drug Sales Market Share by Country (2021-2032) Figure 47. Asia Pacific Chagas Disease Drug Revenue Market Share by Country (2021-2032) Figure 48. China Chagas Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Japan Chagas Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. South Korea Chagas Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. India Chagas Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Australia Chagas Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Taiwan Chagas Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Southeast Asia Chagas Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Southeast Asia Chagas Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. South America Chagas Disease Drug Market Size by Country in 2025 Figure 57. South America Chagas Disease Drug Sales Market Share by Country (2021-2032) Figure 58. South America Chagas Disease Drug Revenue Market Share by Country (2021-2032) Figure 59. Brazil Chagas Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Argentina Chagas Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Chile Chagas Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Middle East and Africa Chagas Disease Drug Market Size by Country in 2025 Figure 63. Middle East and Africa Chagas Disease Drug Sales Market Share by Country (2021-2032) Figure 64. Middle East and Africa Chagas Disease Drug Revenue Market Share by Country (2021-2032) Figure 65. Egypt Chagas Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. South Africa Chagas Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Israel Chagas Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Türkiye Chagas Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. GCC Countries Chagas Disease Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 70. Global Chagas Disease Drug Sales Market Share by Type (2021-2032) Figure 71. Global Chagas Disease Drug Revenue Market Share by Type (2021-2032) Figure 72. Global Chagas Disease Drug Price (US$/unit) by Type (2021-2032) Figure 73. Global Chagas Disease Drug Sales Market Share by Application (2021-2032) Figure 74. Global Chagas Disease Drug Revenue Market Share by Application (2021-2032) Figure 75. Global Chagas Disease Drug Price (US$/unit) by Application (2021-2032) Figure 76. Chagas Disease Drug Value Chain Figure 77. Chagas Disease Drug Production Mode & Process Figure 78. Direct Comparison with Distribution Share Figure 79. Distributors Profiles Figure 80. Chagas Disease Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • Cz-007
  • Cz-008
  • D-121
  • DNDI-0690
  • EPLBS-1246
  • EPLBS-967
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Eisai Co Ltd
  • Sanofi
  • Novartis AG
  • GlaxoSmithKline Plc
  • Bayer AG
  • AstraZeneca Plc
  • Oblita Therapeutics BVBA
  • Merck & Co Inc
  • Kancera AB
  • Humanigen Inc
  • Grupo Praxis Pharmaceutical SA
  • Daiichi Sankyo Co Ltd

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Chagas Disease Drug Market Size (2021-2032)
  4. 2.2.2 Global Chagas Disease Drug Sales (2021-2032)
  5. 2.2.3 Global Chagas Disease Drug Market Average Price (2021-2032)
  6. 2.3 Chagas Disease Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Cz-007
  9. 2.3.3 Cz-008
  10. 2.3.4 D-121
  11. 2.3.5 DNDI-0690
  12. 2.3.6 EPLBS-1246
  13. 2.3.7 EPLBS-967
  14. 2.3.8 Others
  15. 2.4 Chagas Disease Drug by Application
  16. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  17. 2.4.2 Hospital
  18. 2.4.3 Clinic
  19. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Chagas Disease Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Chagas Disease Drug Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Chagas Disease Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Chagas Disease Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Chagas Disease Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Chagas Disease Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Chagas Disease Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Chagas Disease Drug, Established Date
  9. 3.9 Global Chagas Disease Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Eisai Co Ltd
  2. 4.1.1 Eisai Co Ltd Company Information
  3. 4.1.2 Eisai Co Ltd Business Overview
  4. 4.1.3 Eisai Co Ltd Chagas Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Eisai Co Ltd Chagas Disease Drug Product Portfolio
  6. 4.1.5 Eisai Co Ltd Recent Developments
  7. 4.2 Sanofi
  8. 4.2.1 Sanofi Company Information
  9. 4.2.2 Sanofi Business Overview
  10. 4.2.3 Sanofi Chagas Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Sanofi Chagas Disease Drug Product Portfolio
  12. 4.2.5 Sanofi Recent Developments
  13. 4.3 Novartis AG
  14. 4.3.1 Novartis AG Company Information
  15. 4.3.2 Novartis AG Business Overview
  16. 4.3.3 Novartis AG Chagas Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Novartis AG Chagas Disease Drug Product Portfolio
  18. 4.3.5 Novartis AG Recent Developments
  19. 4.4 GlaxoSmithKline Plc
  20. 4.4.1 GlaxoSmithKline Plc Company Information
  21. 4.4.2 GlaxoSmithKline Plc Business Overview
  22. 4.4.3 GlaxoSmithKline Plc Chagas Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 GlaxoSmithKline Plc Chagas Disease Drug Product Portfolio
  24. 4.4.5 GlaxoSmithKline Plc Recent Developments
  25. 4.5 Bayer AG
  26. 4.5.1 Bayer AG Company Information
  27. 4.5.2 Bayer AG Business Overview
  28. 4.5.3 Bayer AG Chagas Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Bayer AG Chagas Disease Drug Product Portfolio
  30. 4.5.5 Bayer AG Recent Developments
  31. 4.6 AstraZeneca Plc
  32. 4.6.1 AstraZeneca Plc Company Information
  33. 4.6.2 AstraZeneca Plc Business Overview
  34. 4.6.3 AstraZeneca Plc Chagas Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 AstraZeneca Plc Chagas Disease Drug Product Portfolio
  36. 4.6.5 AstraZeneca Plc Recent Developments
  37. 4.7 Oblita Therapeutics BVBA
  38. 4.7.1 Oblita Therapeutics BVBA Company Information
  39. 4.7.2 Oblita Therapeutics BVBA Business Overview
  40. 4.7.3 Oblita Therapeutics BVBA Chagas Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Oblita Therapeutics BVBA Chagas Disease Drug Product Portfolio
  42. 4.7.5 Oblita Therapeutics BVBA Recent Developments
  43. 4.8 Merck & Co Inc
  44. 4.8.1 Merck & Co Inc Company Information
  45. 4.8.2 Merck & Co Inc Business Overview
  46. 4.8.3 Merck & Co Inc Chagas Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Merck & Co Inc Chagas Disease Drug Product Portfolio
  48. 4.8.5 Merck & Co Inc Recent Developments
  49. 4.9 Kancera AB
  50. 4.9.1 Kancera AB Company Information
  51. 4.9.2 Kancera AB Business Overview
  52. 4.9.3 Kancera AB Chagas Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Kancera AB Chagas Disease Drug Product Portfolio
  54. 4.9.5 Kancera AB Recent Developments
  55. 4.10 Humanigen Inc
  56. 4.10.1 Humanigen Inc Company Information
  57. 4.10.2 Humanigen Inc Business Overview
  58. 4.10.3 Humanigen Inc Chagas Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Humanigen Inc Chagas Disease Drug Product Portfolio
  60. 4.10.5 Humanigen Inc Recent Developments
  61. 4.11 Grupo Praxis Pharmaceutical SA
  62. 4.11.1 Grupo Praxis Pharmaceutical SA Company Information
  63. 4.11.2 Grupo Praxis Pharmaceutical SA Business Overview
  64. 4.11.3 Grupo Praxis Pharmaceutical SA Chagas Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Grupo Praxis Pharmaceutical SA Chagas Disease Drug Product Portfolio
  66. 4.11.5 Grupo Praxis Pharmaceutical SA Recent Developments
  67. 4.12 Daiichi Sankyo Co Ltd
  68. 4.12.1 Daiichi Sankyo Co Ltd Company Information
  69. 4.12.2 Daiichi Sankyo Co Ltd Business Overview
  70. 4.12.3 Daiichi Sankyo Co Ltd Chagas Disease Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Daiichi Sankyo Co Ltd Chagas Disease Drug Product Portfolio
  72. 4.12.5 Daiichi Sankyo Co Ltd Recent Developments
5 Global Chagas Disease Drug Market Scenario by Region
  1. 5.1 Global Chagas Disease Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Chagas Disease Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Chagas Disease Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Chagas Disease Drug Sales by Region: 2027-2032
  5. 5.3 Global Chagas Disease Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Chagas Disease Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Chagas Disease Drug Revenue by Region: 2027-2032
  8. 5.4 North America Chagas Disease Drug Market Facts & Figures by Country
  9. 5.4.1 North America Chagas Disease Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Chagas Disease Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Chagas Disease Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Chagas Disease Drug Market Facts & Figures by Country
  16. 5.5.1 Europe Chagas Disease Drug Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Chagas Disease Drug Sales by Country (2021-2032)
  18. 5.5.3 Europe Chagas Disease Drug Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Chagas Disease Drug Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Chagas Disease Drug Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Chagas Disease Drug Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Chagas Disease Drug Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Chagas Disease Drug Market Facts & Figures by Country
  41. 5.7.1 South America Chagas Disease Drug Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Chagas Disease Drug Sales by Country (2021-2032)
  43. 5.7.3 South America Chagas Disease Drug Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Chagas Disease Drug Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Chagas Disease Drug Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Chagas Disease Drug Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Chagas Disease Drug Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Chagas Disease Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Chagas Disease Drug Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Chagas Disease Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Chagas Disease Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Chagas Disease Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Chagas Disease Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Chagas Disease Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Chagas Disease Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Chagas Disease Drug Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Chagas Disease Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Chagas Disease Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Chagas Disease Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Chagas Disease Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Chagas Disease Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Chagas Disease Drug Value Chain Analysis
  2. 8.1.1 Chagas Disease Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Chagas Disease Drug Production Mode & Process
  5. 8.2 Chagas Disease Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Chagas Disease Drug Distributors
  8. 8.2.3 Chagas Disease Drug Customers
9 Global Chagas Disease Drug Analyzing Market Dynamics
  1. 9.1 Chagas Disease Drug Industry Trends
  2. 9.2 Chagas Disease Drug Industry Drivers
  3. 9.3 Chagas Disease Drug Industry Opportunities and Challenges
  4. 9.4 Chagas Disease Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst